NEW YORK, March 30, 2023 — Anavex has announced encouraging preliminary results from a 48-week Phase 2 extension study on
their lead drug candidate, ANAVEX®2-73 (blarcamesine), for patients with
Parkinson’s disease dementia. The biopharmaceutical company, known for its
innovative approach to neurodegenerative and neurodevelopmental disorders,
revealed that the study met its primary and secondary objectives, showing
improvements in clinical symptoms over the study period. 

The study focused on evaluating the safety, tolerability, and efficacy of ANAVEX®2-73. Utilizing
the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) and other clinical measures, the results indicated significant
improvements in motor and non-motor symptoms of Parkinson’s disease patients.
These findings suggest that ANAVEX®2-73 has the potential to slow and
potentially reverse the symptoms of this debilitating disease. 

During the study, patients who resumed treatment with ANAVEX®2-73 after a drug holiday showed
consistent clinical improvements. This trend was observed across various
efficacy endpoints, including the Clinical Global Impression – Improvement
(CGI-I) and the Montreal Cognitive Assessment (MoCA). 

Dr. Christopher U Missling, CEO of Anavex Life Sciences, expressed optimism about the study outcomes: “It is encouraging
that the clinical symptoms consistently improved over time under active
ANAVEX®2-73 treatment. This data suggests that ANAVEX®2-73 could address the
urgent unmet needs in Parkinson’s disease treatment.” 

Anavex plans to initiate a pivotal trial for ANAVEX®2-73 in Parkinson’s disease, further supported by a research grant from
the Michael J. Fox Foundation. The foundation has previously funded preclinical
studies that highlighted ANAVEX®2-73’s disease-modifying potential. 

Anavex Life Sciences continues to advance its therapeutic product platform, which includes
drug candidates for Alzheimer’s disease, Rett syndrome, and other central
nervous system disorders. As the research progresses, Anavex aims to bring new
hope to patients suffering from these challenging diseases. See related link for more information. 

Follow Anavex on https://www.instagram.com/anavexlifesci/